Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1221 24.65 (2.06%) Market Cap: 715.43 Bil Enterprise Value: 715.99 Bil PE Ratio: 22.55 PB Ratio: 2.40 GF Score: 93/100

Half Year 2022 Aurobindo Pharma Ltd Earnings Call Transcript

Nov 09, 2021 / 03:00AM GMT
Release Date Price: ₹677 (+0.74%)
Operator

Ladies and gentlemen, welcome to Quarter 2 FY '22 Earnings Conference Call of Aurobindo Pharma Limited. (Operator Instructions) I now hand the conference over to Mr. Arvind Bothra. Thank you, and over to you, sir.

Arvind Bothra
Aurobindo Pharma Limited - Head of IR & Corporate Communications

Thank you, Aditya. Good morning, and warm welcome to our second quarter FY '22 earnings call. I'm Arvind Bothra from the Investor Relations team of Aurobindo Pharma Limited. We hope you have received the FY '22 financials and the press release that we sent out yesterday. The same is available on our website as well. With me, we have our senior management team, represented by Mr. P.V. Ramprasad Reddy; Chairman, Aurobindo Pharma USA; Mr. N Govindarajan, Managing Director Aurobindo Pharma Limited; Mr. Sanjeev Dani, COO and Head of Formulations; Mr. Santhanam Subramanian, Group CFO; and Mr. Swami Iyer , CFO, Aurobindo Pharma USA.

We will begin the call with summary highlights from the management, followed by an interactive Q&A session. Please note that some of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot